Benefits of Using Heterologous Polyclonal Antibodies and Potential Applications to New and Undertreated Infectious Pathogens

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2016 Jan 24

PMID 26802604

Citations 21

Authors

Rashmi Dixit

Jenny Herz

Richard Dalton

Robert Booy

Affiliations

Soon will be listed here.

Abstract

Background: Passive immunotherapy using polyclonal antibodies (immunoglobulins) has been used for over a century in the treatment and post-exposure prophylaxis of various infections and toxins. Heterologous polyclonal antibodies are obtained from animals hyperimmunised with a pathogen or toxin.

Aims: The aims of this review are to examine the history of animal polyclonal antibody therapy use, their development into safe and effective products and the potential application to humans for emerging and neglected infectious diseases.

Methods: A literature search of OVID Medline and OVID Embase databases was undertaken to identify articles on the safety, efficacy and ongoing development of polyclonal antibodies. The search contained database-specific MeSH and EMTREE terms in combination with pertinent text-words: polyclonal antibodies and rare/neglected diseases, antivenins, immunoglobulins, serum sickness, anaphylaxis, drug safety, post marketing surveillance, rabies, human influenza, Dengue, West Nile, Nipah, Hendra, Marburg, MERS, Hemorrhagic Fever Virus, and Crimean-Congo. No language limits were applied. The final search was completed on 20.06.2015. Of 1960 articles, title searches excluded many irrelevant articles, yielding 303 articles read in full. Of these, 179 are referenced in this study.

Results: Serum therapy was first used in the 1890s against diphtheria. Early preparation techniques yielded products contaminated with reactogenic animal proteins. The introduction of enzymatic digestion, and purification techniques substantially improved their safety profile. The removal of the Fc fragment of antibodies further reduces hypersensitivity reactions. Clinical studies have demonstrated the efficacy of polyclonal antibodies against various infections, toxins and venoms. Products are being developed against infections for which prophylactic and therapeutic options are currently limited, such as avian influenza, Ebola and other zoonotic viruses.

Conclusions: Polyclonal antibodies have been successfully applied to rabies, envenomation and intoxication. Polyclonal production provides an exciting opportunity to revolutionise the prognosis of both longstanding neglected tropical diseases as well as emerging infectious threats to humans.

Citing Articles

A comprehensive analysis of the major specificities of anti-human T lymphocyte porcine immunoglobulin (p-ATG).

Zou H, Yin W, Geng P, Lin L, Nie X, Tao Z Ann Hematol. 2024; 104(1):761-771.

PMID: 39402313 PMC: 11868322. DOI: 10.1007/s00277-024-06028-9.

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.

Martinez E, Chang W, Chen W, Hajduczki A, Thomas P, Jensen J iScience. 2024; 27(10):110624.

PMID: 39351195 PMC: 11440237. DOI: 10.1016/j.isci.2024.110624.

Comparison of neutralization potency across passive immunotherapy approaches as potential treatments for emerging infectious diseases.

Ranjbaran H, Ehteshaminia Y, Nadernezhad M, Jalali S, Jadidi-Niaragh F, Pagheh A Heliyon. 2024; 10(1):e23478.

PMID: 38226283 PMC: 10788261. DOI: 10.1016/j.heliyon.2023.e23478.

Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for .

Aggarwal S, Selvaraj S, Subramanian J, Vijayalakshmi M, Patankar S, Srivastava S Diagnostics (Basel). 2023; 13(5).

PMID: 36899977 PMC: 10001162. DOI: 10.3390/diagnostics13050835.

Diagnosis and Treatment for Shiga Toxin-Producing Associated Hemolytic Uremic Syndrome.

Liu Y, Thaker H, Wang C, Xu Z, Dong M Toxins (Basel). 2023; 15(1).

PMID: 36668830 PMC: 9862836. DOI: 10.3390/toxins15010010.

References

Schaeffer T, Khatri V, Reifler L, Lavonas E . Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med. 2012; 19(2):121-31. DOI: 10.1111/j.1553-2712.2011.01276.x. View

Radulescu L, Antohe F, Jinga V, Ghetie V, Simionescu M . Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells. Hum Immunol. 2004; 65(6):578-85. DOI: 10.1016/j.humimm.2004.02.029. View

Sergeyev N, Chepurnov A, Netesov S . Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis. 1999; 179 Suppl 1:S218-23. DOI: 10.1086/514294. View

Bucaretchi F, Douglas J, Fonseca M, Zambrone F, Vieira R . [Snake bites in children: antivenom early reaction frequency in patients pretreated with histamine antagonists H1 and H2 and hydrocortisone]. Rev Inst Med Trop Sao Paulo. 1994; 36(5):451-7. DOI: 10.1590/s0036-46651994000500010. View

Otero R, Gutierrez J, Rojas G, Nunez V, Diaz A, Miranda E . A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon. 1999; 37(6):895-908. DOI: 10.1016/s0041-0101(98)00220-7. View

Solano S, Segura A, Leon G, Gutierrez J, Burnouf T . Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. Biologicals. 2012; 40(2):129-33. DOI: 10.1016/j.biologicals.2011.11.006. View

Lutsch C, Grandgeorge M, Scherrmann J . Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin. Toxicon. 1997; 35(3):411-22. DOI: 10.1016/s0041-0101(96)00144-4. View

Simmons C, Bernasconi N, Suguitan A, Mills K, Ward J, Vinh Chau N . Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007; 4(5):e178. PMC: 1880850. DOI: 10.1371/journal.pmed.0040178. View

Leon G, Monge M, Rojas E, Lomonte B, Gutierrez J . Comparison between IgG and F(ab')(2) polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon. 2001; 39(6):793-801. DOI: 10.1016/s0041-0101(00)00209-9. View

10.

Offerman S, Smith T, Derlet R . Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?. West J Med. 2001; 175(2):88-91. PMC: 1071493. DOI: 10.1136/ewjm.175.2.88. View

11.

Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R . Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Disord Drug Targets. 2013; 13(1):34-45. DOI: 10.2174/18715265112129990006. View

12.

Cotten M, Watson S, Kellam P, Al-Rabeeah A, Makhdoom H, Assiri A . Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet. 2013; 382(9909):1993-2002. PMC: 3898949. DOI: 10.1016/S0140-6736(13)61887-5. View

13.

Dart R, Bogdan G, Heard K, Bucher Bartelson B, Garcia-Ubbelohde W, Bush S . A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom. Ann Emerg Med. 2013; 61(4):458-67. DOI: 10.1016/j.annemergmed.2012.10.008. View

14.

Wu J, Lee C, Cowling B, Yuen K . Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic. Influenza Other Respir Viruses. 2011; 5(Suppl 1):226-9. PMC: 3357494. View

15.

Otten E . Antivenin therapy in the emergency department. Am J Emerg Med. 1983; 1(1):83-93. DOI: 10.1016/0735-6757(83)90040-2. View

16.

Isbister G, Brown S, MacDonald E, White J, Currie B . Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Med J Aust. 2008; 188(8):473-6. DOI: 10.5694/j.1326-5377.2008.tb01721.x. View

17.

Chippaux J, Goyffon M . Venoms, antivenoms and immunotherapy. Toxicon. 1998; 36(6):823-46. DOI: 10.1016/s0041-0101(97)00160-8. View

18.

Burnouf T, Griffiths E, Padilla A, Seddik S, Stephano M, Gutierrez J . Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals. 2004; 32(3):115-28. PMC: 7128792. DOI: 10.1016/j.biologicals.2004.07.001. View

19.

LoVecchio F, Klemens J, Roundy E, Klemens A . Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med. 2004; 14(4):220-1. DOI: 10.1580/1080-6032(2003)14[220:ssfaoa]2.0.co;2. View

20.

Boyer L, Theodorou A, Berg R, Mallie J, Chavez-Mendez A, Garcia-Ubbelohde W . Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009; 360(20):2090-8. DOI: 10.1056/NEJMoa0808455. View